TL;DR
This systematic review synthesizes evidence from rodent models, revealing that exercise interventions (running and swimming) significantly ameliorate Alzheimer's disease (AD) pathology by modulating amyloid processing, neuroinflammation, mitochondrial function, and synaptic plasticity. The authors propose an "exercise-microbiota-brain" framework, highlighting the gut microbiome's crucial role and suggesting personalized, multimodal therapeutic strategies for AD.
What Problem Does This Paper Address?
Alzheimer's disease (AD) is a devastating neurodegenerative disorder with limited effective pharmacological treatments. Existing therapies offer only symptomatic relief and do not halt disease progression. This highlights the urgent need for safe and effective non-pharmacological interventions. Exercise has emerged as a promising candidate, demonstrating broad therapeutic effects in preclinical AD models. However, the precise molecular mechanisms by which exercise confers neuroprotection remain incompletely understood, hindering its translation into clinical practice. This paper aims to systematically review and synthesize the mechanistic evidence from rodent models of AD concerning exercise interventions, focusing on running and swimming, and to propose a framework for clinical translation.
Methods
The authors conducted a systematic review of preclinical studies using transgenic rodent models of AD. They employed the PRISMA 2020 guidelines and the PICOS schema to define their search scope, focusing on exercise interventions (running, swimming, microbiota modulation) and their effects on canonical AD pathological readouts. Methodological quality and risk of bias were assessed using the SYRCLE tool.
Additionally, the study involved re-analysis of publicly available transcriptomic datasets (RNA-sequencing) from AD mouse models subjected to antibiotic treatment (ABX) and methionine restriction (MR). This multi-omics approach allowed for the identification of differentially expressed genes (DEGs) and the construction of protein-protein interaction (PPI) networks to uncover shared molecular mechanisms. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to identify enriched pathways.
Datasets
The study re-analyzed three publicly available RNA-sequencing datasets from the Gene Expression Omnibus (GEO) database:
- GSE185407: Male APPPS1-21 mice treated with antibiotics (ABX) vs. controls.
- GSE154428: Male 5xFAD mice treated with antibiotics (ABX) vs. controls.
- GSE164618: Male AD mice on a methionine-restricted (MR) diet vs. males on standard chow.
No new benchmarks were introduced.
Key Insights and Ideas
- Exercise as a Multi-Target Therapy: Exercise isn't just about physical fitness; it profoundly impacts multiple AD-related pathological pathways simultaneously, making it a powerful therapeutic modality.
- The Gut-Brain Axis is Key: The gut microbiome plays a critical role in mediating exercise's benefits. Exercise reshapes the gut microbiota, influencing the gut-brain axis and promoting neuroimmune homeostasis.
- Running vs. Swimming Nuances: While both running and swimming are beneficial, they may have distinct advantages. Swimming's low-impact nature makes it suitable for comorbid conditions, while running might offer different benefits in terms of specific molecular pathways.
- Identifying Core Regulatory Genes: Through transcriptomic analysis and PPI networks, the study identified potential key genes (e.g., Tlr4, Cdc42, F13a1) that might act as central regulators in exercise-mediated neuroprotection and cognitive resilience.
- Need for a Coordinated Framework: The authors propose an "exercise-microbiota-brain" mechanistic framework to guide personalized, exercise-based therapeutic strategies.
Key Results
- Amelioration of AD Pathology: Exercise interventions in rodent models consistently showed improvements in:
- Modulating amyloid precursor protein (APP) processing and β-amyloid (Aβ) production/clearance.
- Restoring mitochondrial integrity and function.
- Attenuating neuroinflammatory responses.
- Enhancing synaptic plasticity.
- Upregulating neurotrophic factors.
- Transcriptomic Insights: Analysis of transcriptomic data revealed differentially expressed genes (DEGs) in response to ABX and MR interventions, implicating pathways related to neuroinflammation, immune regulation, and synaptic transmission.
- PPI Network Analysis: A high-confidence protein-protein interaction (PPI) network identified potential hub genes (Tlr4, Cdc42, F13a1) that may play significant roles in neuroimmune regulation and cognitive protection.
Limitations and Future Work
- Model Heterogeneity: The study acknowledges the significant heterogeneity across different AD transgenic models, which can influence exercise outcomes. Future research needs to carefully consider and account for these model-specific differences.
- Sex Differences: The authors highlight that sex is an underappreciated factor, with many preclinical studies favoring male animals. Future research must include female animals and perform sex-stratified analyses to ensure generalizability.
- Translational Bottlenecks: While preclinical evidence is strong, translating these findings to humans faces challenges, including:
- Delineating optimal exercise "doses" (intensity, duration, modality) across different AD stages.
- Clarifying peripheral-central immune crosstalk.
- Validating mechanisms in human studies.
- Addressing poor adherence and motivational deficits in AD patients.
- Future Directions:
- Integrate multi-omics profiling (transcriptomics, metabolomics, single-cell sequencing) with clinical data for personalized interventions.
- Conduct mechanism-integrated clinical trials that concurrently assess gut microbiota, biomarkers, and cognitive outcomes.
- Develop standardized protocols for multimodal interventions (exercise, diet, cognitive training).
- Utilize translational platforms (e.g., nonhuman primate models, organoid systems) to validate key mechanisms.
- Focus on combining exercise with complementary interventions for accelerated clinical translation.
Summary updated